$NRIX News

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%

Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments

Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period

Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33

Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40

BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update